Biogen Idec/PDL BioPharma Present Daclizumab CHOICE Data At ECTRIMS
This article was originally published in The Pink Sheet Daily
Firms plan to initiate a monotherapy Phase II trial in relapsing MS patients by the end of 2007.
You may also be interested in...
Activist investor Carl Icahn is among those interested in the biotech.
Phase II monotherapy trial for the monoclonal antibody will initiate in the second half of 2007, PDL tells “The Pink Sheet” DAILY.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.